A Phase 2 interventional study of LGX818 and Cetuximab in Colorectal Cancer, sponsored by Pfizer. Completed at 52 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-23.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing encorafenib in Colorectal Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. encorafenib · Colorectal Neoplasms.
Among the 16 studies testing encorafenib in Colorectal Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2012, is one of 9 in phase 2, and was the 2nd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →5 of the 16 studies testing encorafenib in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Vall d'Hebron Institute of Oncology · Sites in Spain
Ages 18+
Federation Francophone de Cancerologie Digestive · Sites in France
Ages 18+
Oslo University Hospital · Sites in Norway
Ages 18+
By country, each count listing its studies:
encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 2
First in 2011; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 156 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 95 across the 16 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
73 studies in Colorectal Neoplasms by Pfizer: 6 open now, 14 under way, 3 of them phase 3. Of 58 finished, 28 (48%) have results posted.
Among the 73 studies in Colorectal Neoplasms by Pfizer, this one is the 23rd largest by enrollment of the 68 interventional ones that give a count, is the only one that started in 2012, is one of 21 in phase 2, and was the 27th registered.
Pfizer’s Colorectal Neoplasms studies by the year they started, since 1999.
3 of the studies testing encorafenib in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
| NCT06411600Vall d'Hebron Institute of OncologyCombination Therapy for BRAF-V600E Metastatic CRCm | 2027-05-01 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing encorafenib in Colorectal Neoplasms, from their registry updates:
Among Pfizer’s 73 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LGX818 · Drug: Cetuximab
Drug: LGX818 · Drug: Cetuximab · Drug: BYL719
Phase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 1
DLTs were defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first 28 days of treatment and meets any of the criteria included blood and lymphatic system disorders, investigations (blood, renal, hepatic, metabolic), skin and subcutaneous tissue disorders: rash, HFSR (hand foot skin reaction) and/or photosensitivity, metabolism and nutrition disorders: hyperglycemia, gastrointestinal disorders, cardiac disorders, vascular disorders, general disorders and administration site conditions, tumor lysis syndrome, ophthalmologic and other adverse events: study drug-related fever, alkaline phosphatase elevation.
Time frame: Cycle 1: Day 1 to Day 28
Phase 2: Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. Participants who did not progress per RECIST (Response Evaluation Criteria in Solid Tumors) version (v) 1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.
Time frame: From the date of randomization until the first documentation of disease progression or death due to any cause, censored date, whichever occurred first (maximum up to 43 months)
Number of Participants With Treatment - Emergent Adverse Events of Grade 3 or 4 Severity Based on National Cancer Institute of Common Terminology Criteria (NCI-CTCAE), Version 4.0
An AE was any untoward medical occurrence attributed to study drug in participants who received study drug. As per NCI-CTCAE v4.0, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to study drug. Treatment-emergent AEs are between first dose of study drug and up to 30 days after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. Number of participants with any Grade 3 or 4 treatment-emergent AE were reported in this outcome measure.
Time frame: From screening up to 30 days after the last dose of study treatment (for a maximum duration of 43 months, approximately)
Apparent Total Plasma Clearance (CL/F) of LGX818 (Encorafenib)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Apparent Total Plasma Clearance at Steady State (CL/F, ss) of LGX818 (Encorafenib)
Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Apparent Total Plasma Clearance (CL/F) of BYL719 (Alpelisib)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Apparent Total Plasma Clearance at Steady State (CL/F, ss) of BYL719 (Alpelisib)
Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Apparent Terminal Volume of Distribution (Vz/F) of LGX818 (Encorafenib)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Apparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of LGX818 (Encorafenib)
Volume of distribution at steady state is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.
Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Apparent Terminal Volume of Distribution (Vz/F) of BYL719 (Alpelisib)
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Apparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of BYL719 (Alpelisib)
Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.
Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of LGX818 (Encorafenib)
Tmax was defined as the time to reach maximum observed plasma concentration of encorafenib.
Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Time to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of LGX818 (Encorafenib)
Tmax, ss was defined as the time to reach maximum observed plasma concentration of LGX818 (encorafenib) at steady state.
Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of BYL719 (Alpelisib)
Tmax was defined as the time to reach maximum observed plasma concentration of alpelisib.
Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Time to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of BYL719 (Alpelisib)
Tmax, ss was defined as the time to reach maximum observed plasma concentration of BYL719 (alpelisib) at steady state.
Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Time of Last Observed Plasma Concentration (T-last) of LGX818 (Encorafenib)
T-last was defined as the time to reach last observed plasma concentration of encorafenib.
Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Time of Last Observed Plasma Concentration at Steady State (T-last, ss) of LGX818 (Encorafenib)
T-last, ss was defined as the time to reach last observed plasma concentration of encorafenib at steady state.
Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Time of Last Observed Plasma Concentration (T-last) of BYL719 (Alpelisib)
T-last was defined as the time to reach last observed plasma concentration of alpelisib.
Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Time of Last Observed Plasma Concentration at Steady State (T-last, ss) of BYL719 (Alpelisib)
T-last, ss was defined as the time to reach last observed plasma concentration of alpelisib at steady state.
Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Plasma Trough Concentration at Steady State (Ctrough, ss) of LGX818 (Encorafenib)
Ctrough, ss was defined as plasma trough concentration of encorafenib at steady state.
Time frame: Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Plasma Trough Concentration at Steady State (Ctrough, ss) of BYL719 (Alpelisib)
Ctrough, ss was defined as plasma trough concentration of alpelisib at steady state.
Time frame: Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Overall Survival (OS)
OS was defined as the time (in months) from the date of randomization or date of start of treatment to the date of death due to any cause or data censoring date, whichever occurred first. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
Time frame: From the date of randomization or date of start of treatment to the date of death due to any cause or data censoring date, whichever occurred first (up to 43 months)
Overall Response Rate (ORR)
Overall response rate as assessed by the investigator per RECIST v1.1, was defined as percentage of participants with a best overall response of complete response (CR) or partial response (PR), were recorded from date of randomization or date of start of treatment until date of first documentation of progressive disease (PD) or death due to any cause. CR was defined as complete disappearance of all target and non-nodal target lesions, and sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Only confirmed CR and PR are counted (those confirmed at least 4 weeks).
Time frame: From date of randomization or date of start of treatment until date of first documentation of PD or death due to any cause (maximum up to 43 months)
Duration of Response (DOR)
DOR: Time between date of the first documented response (CR or PR) and the date of first documented PD or death due to underlying cancer. If PD or death due to underlying cancer not occurred, then participant was censored at the date of last tumor assessment other than unknown. DOR was calculated for responders (confirmed) only. CR: Disappearance of all target, non-target lesions sustained for \>=4 weeks and any pathological lymph nodes reduced in short axis to \<10mm. PR: \>=30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameter. PD for target lesions: At least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study treatment, with absolute increase of \>=5 mm, or appearance of \>=1 new lesions. PD for non-target lesions: Unequivocal progression of pre-existing lesions/increase in overall tumor burden leading to discontinuation of therapy or appearance of new unequivocal malignant lesion.
Time frame: From the first documentation of OR (confirmed CR or PR) to first documentation of PD/death due to any cause or censoring date, whichever occurred first (up to 43 months)
Time to Response (TTR)
TTR as assessed by investigator according to RECIST v1.1, was defined as the time (in months) from date of randomization or date of start of treatment until first documented response (CR or PR) or data censoring date, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) reduced in short axis to \<10 mm. PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not achieve a confirmed PR or CR, were censored at last adequate tumor assessment date when they did not progress (including deaths not due to underlying disease) or at maximum follow-up (from study start to study end date) when participant had an event for progression-free survival.
Time frame: From the date of randomization or date of start of treatment until first documented response (CR or PR) or data censoring date, whichever occurred first (maximum up to 43 months)
Phase 1b: Progression Free Survival (PFS)
PFS was defined as the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. Participants who did not progress per RECIST v1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.
Time frame: From date of start of treatment to the date of event defined as the first documented progression or death due to any cause, censored date, whichever occurred first (maximum up to 43 months)
Phase 2: Number of Participants With Any Variant in Gene Status at Baseline
Gene alterations/expression relevant to the RAF/MEK/ERK (proto-oncogene serine/threonine-protein kinase/ mitogen-activated ERK kinase/ extracellular signal-regulated kinases) and EGFR/PI3K/AKT (epidermal growth factor receptor/ phosphatidylinositol 3-kinase/ protein kinase B) pathways in tumor tissue, baseline molecular status (mutation/amplification/expression) in tumor tissue of potential predictive markers of tumor response or resistance i.e. BRAF (v-raf murine sarcoma viral oncogene homolog B1), HRAS (harvey rat sarcoma protein), KRAS (V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog B1), NRAS (neuroblastoma RAS viral oncogene homolog), PTEN (phosphatase and tensin homolog), PIK3CA (phosphatidylinositol 3-kinase gene), MAP2K1 (mitogen-activated protein kinase 1), MAP2K2 (mitogen-activated protein kinase 2), ARAF, c-MET, RAF1, EGFR was analyzed.
Time frame: Baseline (Day 1)
| Milestone | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 7 | 9 | 8 | 3 | 8 | 10 | 7 | 50 | 52 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not completed | 2 | 7 | 9 | 8 | 3 | 8 | 10 | 7 | 50 | 51 |
| Withdrew: Adverse event | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 4 | 3 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Withdrew: Participant/guardian decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Physician decision | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 2 | 6 | 5 | 6 | 3 | 7 | 10 | 6 | 39 | 42 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
DLTs were defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first 28 days of treatment and meets any of the criteria included blood and lymphatic system disorders, investigations (blood, renal, hepatic, metabolic), skin and subcutaneous tissue disorders: rash, HFSR (hand foot skin reaction) and/or photosensitivity, metabolism and nutrition disorders: hyperglycemia, gastrointestinal disorders, cardiac disorders, vascular disorders, general disorders and administration site conditions, tumor lysis syndrome, ophthalmologic and other adverse events: study drug-related fever, alkaline phosphatase elevation.
| Participants | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|
| Phase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. Participants who did not progress per RECIST (Response Evaluation Criteria in Solid Tumors) version (v) 1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.
| months | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|
| Phase 2: Progression Free Survival (PFS) | 4.2 (3.0 to 5.1) | 4.9 (4.0 to 7.1) |
An AE was any untoward medical occurrence attributed to study drug in participants who received study drug. As per NCI-CTCAE v4.0, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to study drug. Treatment-emergent AEs are between first dose of study drug and up to 30 days after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. Number of participants with any Grade 3 or 4 treatment-emergent AE were reported in this outcome measure.
| Participants | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment - Emergent Adverse Events of Grade 3 or 4 Severity Based on National Cancer Institute of Common Terminology Criteria (NCI-CTCAE), Version 4.0 | 2 | 4 | 6 | 7 | 3 | 5 | 7 | 6 | 33 | 43 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| liter per hour | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Total Plasma Clearance (CL/F) of LGX818 (Encorafenib) | 16.8 ± 3.60 | 11.7 ± 6.10 | 12.1 ± 5.95 | 12.3 ± 4.96 | 7.69 ± 3.13 | 14.2 ± 5.75 | 14.1 ± 3.65 | 17.8 ± 17.4 | 13.1 ± 5.07 | 10.9 ± 5.70 |
Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| liter per hour | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 8 | — | — | — | — | 17.0 ± 3.42 | 24.4 ± 18.3 | 15.4 ± 4.25 | 22.4 ± 17.7 | — | — |
| Cycle 2 Day 1 | 13.9 ± 4.72 | 31.1 ± 11.9 | 31.6 ± 2.19 | 30.5 ± 12.3 | 32.6 ± 6.88 | 20.2 ± 7.91 | 22.7 ± 5.68 | 38.4 ± 16.4 | 28.2 ± 8.97 | 23.3 ± 11.6 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| liter per hour | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|
| Apparent Total Plasma Clearance (CL/F) of BYL719 (Alpelisib) | 12.7 ± 2.03 | 12.1 ± 3.96 | 11.6 ± 1.85 | 11.7 ± 5.38 | 15.6 ± 9.61 |
Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| liter per hour | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|
| Cycle 1 Day 8 | 16.5 ± 5.96 | 13.2 ± 2.29 | 13.7 ± 7.20 | 11.6 ± 6.05 | — |
| Cycle 2 Day 1 | 18.3 ± 0.794 | 10.3 ± 1.23 | 12.5 ± 1.60 | 19.0 ± 6.51 | 17.9 ± 10.5 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| liter | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Terminal Volume of Distribution (Vz/F) of LGX818 (Encorafenib) | 104 ± 28.3 | 60.3 ± 25.8 | 62.8 ± 31.8 | 57.2 ± 29.6 | 49.2 ± 12.4 | 75.7 ± 31.6 | 64.6 ± 20.6 | 60.7 ± 44.0 | 63.5 ± 29.9 | 80.9 ± 93.9 |
Volume of distribution at steady state is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.
| liter | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 8 | — | — | — | — | 78.4 ± 13.0 | 98.2 ± 84.5 | 78.6 ± 26.2 | 88.8 ± 53.6 | — | — |
| Cycle 2 Day 1 | 66.8 ± 13.7 | 131 ± 45.8 | 110 ± 41.1 | 142 ± 84.5 | 137 ± 32.9 | 91.6 ± 41.4 | 102 ± 39.9 | 187 ± 89.5 | 117 ± 37.6 | 105 ± 42.2 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| liter | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|
| Apparent Terminal Volume of Distribution (Vz/F) of BYL719 (Alpelisib) | 112 ± 22.0 | 104 ± 31.0 | 105 ± 34.3 | 106 ± 78.6 | 123 ± 50.7 |
Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.
| liter | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|
| Cycle 1 Day 8 | 110 ± 40.7 | 97.0 ± 20.6 | 105 ± 30.2 | 82.5 ± 18.8 | — |
| Cycle 2 Day 1 | 138 ± 20.7 | 75.4 ± 11.2 | 104 ± 10.7 | 144 ± 44.5 | 149 ± 100 |
Tmax was defined as the time to reach maximum observed plasma concentration of encorafenib.
| hour | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of LGX818 (Encorafenib) | 2.00 (1.98 to 2.02) | 1.99 (0.97 to 2.05) | 2.03 (1.00 to 4.00) | 2.17 (1.00 to 5.97) | 1.00 (0.98 to 1.98) | 2.02 (1.00 to 4.02) | 2.00 (0.87 to 5.95) | 3.87 (1.50 to 4.13) | 2.00 (0.93 to 6.12) | 2.03 (0.50 to 8.00) |
Tmax, ss was defined as the time to reach maximum observed plasma concentration of LGX818 (encorafenib) at steady state.
| hour | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 8 | — | — | — | — | 0.98 (0.75 to 4.00) | 1.98 (1.00 to 3.98) | 2.00 (1.12 to 4.02) | 3.92 (0.50 to 4.08) | — | — |
| Cycle 2 Day 1 | 1.51 (1.00 to 2.02) | 2.00 (1.00 to 4.03) | 1.98 (0.97 to 4.00) | 1.98 (1.05 to 2.05) | 2.00 (1.00 to 2.02) | 2.02 (1.05 to 6.00) | 3.00 (1.92 to 7.98) | 2.27 (2.07 to 3.97) | 1.15 (0.98 to 5.93) | 2.00 (1.88 to 6.00) |
Tmax was defined as the time to reach maximum observed plasma concentration of alpelisib.
| hour | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of BYL719 (Alpelisib) | 1.98 (0.98 to 2.00) | 3.97 (1.93 to 6.00) | 2.00 (0.87 to 5.95) | 2.10 (1.50 to 4.50) | 2.05 (1.92 to 8.00) |
Tmax, ss was defined as the time to reach maximum observed plasma concentration of BYL719 (alpelisib) at steady state.
| hour | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|
| Cycle 1 Day 8 | 1.97 (1.00 to 4.00) | 3.99 (1.00 to 7.97) | 2.15 (1.12 to 4.02) | 4.07 (0.00 to 4.10) | — |
| Cycle 2 Day 1 | 2.02 (1.00 to 4.00) | 4.00 (1.05 to 6.00) | 3.93 (2.00 to 5.98) | 4.03 (3.97 to 8.00) | 2.02 (1.00 to 6.00) |
T-last was defined as the time to reach last observed plasma concentration of encorafenib.
| hour | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Time of Last Observed Plasma Concentration (T-last) of LGX818 (Encorafenib) | 23.98 (23.98 to 23.98) | 23.69 (8.00 to 24.00) | 24.03 (22.33 to 24.83) | 23.58 (8.80 to 24.13) | 23.00 (22.52 to 24.30) | 23.06 (7.97 to 24.22) | 22.02 (8.47 to 24.37) | 23.87 (8.23 to 25.92) | 23.85 (8.00 to 24.25) | 23.50 (5.38 to 24.50) |
T-last, ss was defined as the time to reach last observed plasma concentration of encorafenib at steady state.
| hour | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 8 | — | — | — | — | 23.78 (23.75 to 23.92) | 23.36 (7.58 to 23.98) | 23.92 (23.48 to 23.97) | 23.87 (21.83 to 23.95) | — | — |
| Cycle 2 Day 1 | 23.89 (23.88 to 23.90) | 22.13 (7.30 to 23.85) | 14.05 (6.00 to 24.67) | 23.45 (6.00 to 23.98) | 23.97 (7.25 to 24.20) | 23.08 (8.00 to 23.98) | 23.94 (7.00 to 24.38) | 23.42 (22.08 to 23.58) | 23.80 (8.07 to 24.17) | 23.42 (8.00 to 24.48) |
T-last was defined as the time to reach last observed plasma concentration of alpelisib.
| hour | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|
| Time of Last Observed Plasma Concentration (T-last) of BYL719 (Alpelisib) | 23.00 (22.52 to 24.30) | 23.06 (7.97 to 24.22) | 22.76 (8.47 to 24.37) | 23.87 (8.23 to 25.92) | 23.17 (7.92 to 24.50) |
T-last, ss was defined as the time to reach last observed plasma concentration of alpelisib at steady state.
| hour | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|
| Cycle 1 Day 8 | 23.78 (23.75 to 23.92) | 23.36 (7.58 to 23.98) | 23.87 (7.75 to 23.97) | 23.87 (21.83 to 23.95) | — |
| Cycle 2 Day 1 | 23.97 (7.25 to 24.20) | 23.08 (8.00 to 23.98) | 23.94 (7.00 to 24.38) | 23.47 (22.08 to 23.58) | 23.77 (7.00 to 25.50) |
Ctrough, ss was defined as plasma trough concentration of encorafenib at steady state.
| nanogram per milliliter | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Trough Concentration at Steady State (Ctrough, ss) of LGX818 (Encorafenib) | 9.87 ± 6.69 | 20.5 ± 28.0 | 15.7 ± 22.0 | 20.6 ± 18.4 | 7.69 ± 1.76 | 10.4 ± 5.05 | 26.5 ± 31.4 | 29.2 ± NA | 9.24 ± 5.19 | 15.0 ± 17.8 |
Ctrough, ss was defined as plasma trough concentration of alpelisib at steady state.
| nanogram per milliliter | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|
| Plasma Trough Concentration at Steady State (Ctrough, ss) of BYL719 (Alpelisib) | 36.7 ± 21.0 | 108 ± 41.1 | 283 ± 156 | 66.0 ± NA | 141 ± 76.5 |
OS was defined as the time (in months) from the date of randomization or date of start of treatment to the date of death due to any cause or data censoring date, whichever occurred first. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
| months | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 15.0 (14.8 to 15.2) | 5.4 (1.2 to 7.8) | NA (2.9 to NA) | 16.6 (3.9 to 23.5) | 6.6 (5.0 to NA) | 8.7 (3.8 to 27.1) | 9.8 (3.7 to 25.2) | NA (5.3 to NA) | 9.3 (5.8 to 15.6) | 8.5 (6.1 to 15.2) |
Overall response rate as assessed by the investigator per RECIST v1.1, was defined as percentage of participants with a best overall response of complete response (CR) or partial response (PR), were recorded from date of randomization or date of start of treatment until date of first documentation of progressive disease (PD) or death due to any cause. CR was defined as complete disappearance of all target and non-nodal target lesions, and sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Only confirmed CR and PR are counted (those confirmed at least 4 weeks).
| percentage of participants | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 50.0 (1.3 to 98.7) | 14.3 (0.4 to 57.9) | 11.1 (0.3 to 48.2) | 25.0 (3.2 to 65.1) | 33.3 (0.8 to 90.6) | 25.0 (3.2 to 65.1) | 20.0 (2.5 to 55.6) | 0 (0.0 to 41.0) | 24.0 (13.1 to 38.2) | 26.9 (15.6 to 41.0) |
DOR: Time between date of the first documented response (CR or PR) and the date of first documented PD or death due to underlying cancer. If PD or death due to underlying cancer not occurred, then participant was censored at the date of last tumor assessment other than unknown. DOR was calculated for responders (confirmed) only. CR: Disappearance of all target, non-target lesions sustained for \>=4 weeks and any pathological lymph nodes reduced in short axis to \<10mm. PR: \>=30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameter. PD for target lesions: At least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study treatment, with absolute increase of \>=5 mm, or appearance of \>=1 new lesions. PD for non-target lesions: Unequivocal progression of pre-existing lesions/increase in overall tumor burden leading to discontinuation of therapy or appearance of new unequivocal malignant lesion.
| months | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) | 10.6 (NA to NA) | 2.3 (NA to NA) | 21.7 (NA to NA) | 8.1 (5.4 to 10.9) | 3.9 (NA to NA) | 3.6 (2.8 to 4.4) | 3.3 (2.8 to 3.8) | — | 5.6 (2.0 to NA) | 5.3 (2.7 to 10.8) |
TTR as assessed by investigator according to RECIST v1.1, was defined as the time (in months) from date of randomization or date of start of treatment until first documented response (CR or PR) or data censoring date, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) reduced in short axis to \<10 mm. PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not achieve a confirmed PR or CR, were censored at last adequate tumor assessment date when they did not progress (including deaths not due to underlying disease) or at maximum follow-up (from study start to study end date) when participant had an event for progression-free survival.
| months | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Response (TTR) | 2.8 (NA to NA) | 1.4 (NA to NA) | 3.9 (NA to NA) | 4.0 (1.4 to 6.7) | 1.5 (NA to NA) | 3.5 (1.4 to 5.6) | 2.0 (1.4 to 2.5) | — | 1.7 (1.2 to 7.7) | 1.5 (1.4 to 1.7) |
PFS was defined as the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. Participants who did not progress per RECIST v1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.
| months | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|
| Phase 1b: Progression Free Survival (PFS) | 12.0 (10.6 to 13.4) | 3.7 (1.2 to 4.1) | 2.8 (1.3 to 4.3) | 12.0 (1.8 to 12.3) | 5.4 (4.4 to 9.1) | 4.3 (3.8 to 13.6) | 4.1 (1.7 to 5.8) | 4.2 (2.9 to 12.3) |
Gene alterations/expression relevant to the RAF/MEK/ERK (proto-oncogene serine/threonine-protein kinase/ mitogen-activated ERK kinase/ extracellular signal-regulated kinases) and EGFR/PI3K/AKT (epidermal growth factor receptor/ phosphatidylinositol 3-kinase/ protein kinase B) pathways in tumor tissue, baseline molecular status (mutation/amplification/expression) in tumor tissue of potential predictive markers of tumor response or resistance i.e. BRAF (v-raf murine sarcoma viral oncogene homolog B1), HRAS (harvey rat sarcoma protein), KRAS (V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog B1), NRAS (neuroblastoma RAS viral oncogene homolog), PTEN (phosphatase and tensin homolog), PIK3CA (phosphatidylinositol 3-kinase gene), MAP2K1 (mitogen-activated protein kinase 1), MAP2K2 (mitogen-activated protein kinase 2), ARAF, c-MET, RAF1, EGFR was analyzed.
| Participants | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|
| Phase 2: Number of Participants With Any Variant in Gene Status at Baseline | 30 | 34 |
Collected over From screening up to 30 days after the last dose of study treatment (maximum up to 43 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: LGX818 100 mg + Cetuximab | — | 2/2 (100%) | 2/2 (100%) |
| Phase 1b: LGX818 200 mg + Cetuximab | — | 5/7 (71.4%) | 7/7 (100%) |
| Phase 1b: LGX818 400 mg + Cetuximab | — | 6/9 (66.7%) | 9/9 (100%) |
| Phase 1b: LGX818 450 mg + Cetuximab | — | 6/8 (75%) | 8/8 (100%) |
| Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | — | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | — | 5/8 (62.5%) | 8/8 (100%) |
| Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | — | 6/10 (60%) | 10/10 (100%) |
| Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | — | 4/7 (57.1%) | 7/7 (100%) |
| Phase 2: LGX818 200 mg + Cetuximab | — | 25/50 (50%) | 50/50 (100%) |
| Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab | — | 33/52 (63.5%) | 52/52 (100%) |
| Event | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/2 | 1/7 | 1/9 | 0/8 | 0/3 | 0/8 | 0/10 | 1/7 | 2/50 | 1/52 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/2 | 0/7 | 1/9 | 0/8 | 0/3 | 0/8 | 0/10 | 0/7 | 0/50 | 0/52 |
| Abdominal painGastrointestinal disorders | 0/2 | 1/7 | 1/9 | 3/8 | 0/3 | 1/8 | 2/10 | 0/7 | 5/50 | 5/52 |
| Blood bilirubin increasedInvestigations | 0/2 | 0/7 | 1/9 | 1/8 | 1/3 | 0/8 | 0/10 | 0/7 | 0/50 | 0/52 |
| Deep vein thrombosisVascular disorders | 0/2 | 0/7 | 0/9 | 0/8 | 1/3 | 0/8 | 0/10 | 0/7 | 0/50 | 0/52 |
| IleusGastrointestinal disorders | 0/2 | 0/7 | 0/9 | 2/8 | 0/3 | 0/8 | 2/10 | 0/7 | 2/50 | 1/52 |
| VomitingGastrointestinal disorders | 0/2 | 0/7 | 1/9 | 0/8 | 0/3 | 2/8 | 0/10 | 0/7 | 2/50 | 3/52 |
| NauseaGastrointestinal disorders | 0/2 | 0/7 | 0/9 | 0/8 | 0/3 | 2/8 | 0/10 | 0/7 | 2/50 | 2/52 |
| Cardiac arrestCardiac disorders | 0/2 | 1/7 | 0/9 | 0/8 | 0/3 | 0/8 | 0/10 | 0/7 | 1/50 | 0/52 |
| Cardiac failure congestiveCardiac disorders | 0/2 | 1/7 | 0/9 | 0/8 | 0/3 | 0/8 | 0/10 | 0/7 | 1/50 | 0/52 |
| Event | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab |
|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/2 | 1/7 | 1/9 | 4/8 | 0/3 | 4/8 | 8/10 | 5/7 | 23/50 | 30/52 |
| FatigueGeneral disorders | 2/2 | 2/7 | 5/9 | 5/8 | 1/3 | 2/8 | 6/10 | 3/7 | 25/50 | 27/52 |
| HallucinationPsychiatric disorders | 2/2 | 0/7 | 0/9 | 0/8 | 0/3 | 0/8 | 0/10 | 0/7 | 0/50 | 0/52 |
| DiarrhoeaGastrointestinal disorders | 0/2 | 0/7 | 3/9 | 4/8 | 0/3 | 7/8 | 5/10 | 5/7 | 14/50 | 29/52 |
| VomitingGastrointestinal disorders | 1/2 | 2/7 | 5/9 | 4/8 | 0/3 | 4/8 | 7/10 | 3/7 | 17/50 | 25/52 |
| Weight decreasedInvestigations | 1/2 | 2/7 | 1/9 | 3/8 | 1/3 | 5/8 | 3/10 | 2/7 | 9/50 | 19/52 |
| Lipase increasedInvestigations | 0/2 | 1/7 | 1/9 | 0/8 | 0/3 | 1/8 | 1/10 | 4/7 | 16/50 | 7/52 |
| Decreased appetiteMetabolism and nutrition disorders | 1/2 | 2/7 | 2/9 | 2/8 | 1/3 | 2/8 | 1/10 | 4/7 | 16/50 | 19/52 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/2 | 1/7 | 0/9 | 1/8 | 1/3 | 2/8 | 4/10 | 4/7 | 5/50 | 18/52 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/2 | 0/7 | 0/9 | 1/8 | 1/3 | 0/8 | 2/10 | 4/7 | 1/50 | 6/52 |
| Age, Customized(Participants) | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <65 years | 1 | 4 | 7 | 5 | 2 | 4 | 8 | 6 | 32 | 38 | 107 |
| >=65 years | 1 | 3 | 2 | 3 | 1 | 4 | 2 | 1 | 18 | 14 | 49 |
| Sex: Female, Male(Participants) | Phase 1b: LGX818 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + Cetuximab | Phase 1b: LGX818 400 mg + Cetuximab | Phase 1b: LGX818 450 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab | Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab | Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab | Phase 2: LGX818 200 mg + Cetuximab | Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 6 | 4 | 1 | 5 | 7 | 5 | 36 | 27 | 96 |
| Male | 0 | 4 | 3 | 4 | 2 | 3 | 3 | 2 | 14 | 25 | 60 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
No publications or documents are linked to this record.
Ran from Nov 2012 to primary completion in Oct 2015, 35 months.
Results were first posted in Jun 2021, 5 years 7 months after primary completion. A results delay was requested in Jul 2017.
Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 35 months is close to that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Encorafenib · Cetuximab · Alpelisib